Gonzalez Santiago TM, Wetter DA, Kalaaji AN, Limper AH, Lehman
Fo
JS. Pneumocystis jiroveci pneumonia in patients treated with systemic
immunosuppressive agents for dermatologic conditions: a systematic
review with recommendations for prophylaxis. Int J Dermatol 2016;
55: 823-830.
iew
ev
10
rR
Schneider MM, Hoepelman AI, Eeftinck Schattenkerk JK et al. A
11
controlled trial of aerosolized pentamidine or trimethoprim-
12
sulfamethoxazole as primary prophylaxis against Pneumocystis
13
carinii pneumonia in patients with human immunodeficiency virus
14
infection. The Dutch AIDS Treatment Group. N Engl J Med 1992;
15
327: 1836-1841.
16
ly
On
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Page 12 of 18
Prasad GVR, Beckley J, Mathur M et al. Safety and efficacy of
17
prophylaxis for Pneumocystis jirovecii pneumonia involving
18
trimethoprim-sulfamethoxazole
dose
11
The Journal of Dermatology
reduction
in
kidney
Page 13 of 18
transplantation. BMC Infect Dis 2019; 19: 311.
Leoung GS, Stanford JF, Giordano MF et al. Trimethoprim-
sulfamethoxazole (TMP-SMZ) dose escalation versus direct
rechallenge for Pneumocystis Carinii pneumonia prophylaxis in
human immunodeficiency virus-infected patients with previous
adverse reaction to TMP-SMZ. J Infect Dis 2001; 184: 992-997.
Abe Y, Fujibayashi K, Nishizaki Y et al. Conventional-dose Versus
rR
Fo
Half-dose Sulfamethoxazole-trimethoprim for the Prophylaxis of
Pneumocystis Pneumonia in Patients with Systemic Rheumatic
10
Disease: A Non-blind, Randomized Controlled Trial. Acta Med
11
Okayama 2019; 73: 85-89.
iew
ly
On
12
ev
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
The Journal of Dermatology
Lehman JS, Kalaaji AN. Role of primary prophylaxis for
13
pneumocystis pneumonia in patients treated with systemic
14
corticosteroids or other immunosuppressive agents for immune-
15
mediated dermatologic conditions. J Am Acad Dermatol 2010; 63:
16
815-823.
17
18
Park JW, Curtis JR, Moon J, Song YW, Kim S, Lee EB. Prophylactic
effect
of
trimethoprim-sulfamethoxazole
12
The Journal of Dermatology
for
pneumocystis
The Journal of Dermatology
pneumonia in patients with rheumatic diseases exposed to prolonged
high-dose glucocorticoids. Ann Rheum Dis 2018; 77: 644-649.
Torre-Cisneros J, De la Mata M, Pozo JC et al. Randomized trial of
weekly sulfadoxine/pyrimethamine vs. daily low-dose trimethoprim-
sulfamethoxazole for the prophylaxis of Pneumocystis carinii
pneumonia after liver transplantation. Clin Infect Dis 1999; 29: 771-
774.
El-Sadr WM, Luskin-Hawk R, Yurik TM et al. A randomized trial of
ev
rR
Fo
daily and thrice-weekly trimethoprim-sulfamethoxazole for the
prevention
11
immunodeficiency virus-infected persons. Terry Beirn Community
12
Programs for Clinical Research on AIDS (CPCRA). Clin Infect Dis
13
1999; 29: 775-783.
10
Pneumocystis
carinii
pneumonia
in
human
ly
On
10
14
of
iew
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Page 14 of 18
Podzamczer D, Salazar A, Jimenez J et al. Intermittent trimethoprim-
15
sulfamethoxazole compared with dapsone-pyrimethamine for the
16
simultaneous primary prophylaxis of Pneumocystis pneumonia and
17
toxoplasmosis in patients infected with HIV. Ann Intern Med 1995;
18
122: 755-761.
13
The Journal of Dermatology
Page 15 of 18
11
sulfamethoxazole. Cmaj 2011; 183: 1851-1858.
Ho JM, Juurlink DN. Considerations when prescribing trimethoprim-
12
Ohmura S-i, Naniwa T, Tamechika S-y et al. Effectiveness and safety
of
Pneumocystis jirovecii pneumonia in patients with systemic rheumatic
diseases: A retrospective multicenter study. Journal of Infection and
Chemotherapy 2019; 25: 253-261.
dose
sulfamethoxazole/trimethoprim
therapy
for
Masur H, Brooks JT, Benson CA et al. Prevention and treatment of
ev
13
rR
lower
Fo
opportunistic infections in HIV-infected adults and adolescents:
10
Updated Guidelines from the Centers for Disease Control and
11
Prevention, National Institutes of Health, and HIV Medicine
12
Association of the Infectious Diseases Society of America. Clin Infect
13
Dis 2014; 58: 1308-1311.
14
ly
On
14
iew
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
The Journal of Dermatology
Amber KT, Lamberts A, Solimani F et al. Determining the Incidence
15
of Pneumocystis Pneumonia in Patients With Autoimmune Blistering
16
Diseases Not Receiving Routine Prophylaxis. JAMA Dermatol 2017;
17
153: 1137-1141.
18
14
The Journal of Dermatology
The Journal of Dermatology
FIGURE LEGEND
Figure 1. Box-and-whisker plot shows the day of onset of each adverse
event
TABLES
Table 1. Patient characteristics
Table 2. The incidence of adverse events comparison with previous reports
El-Sadr WM, et al.
rR
Fo
Daily administered cases of this study versus daily administered cases of
iew
ev
10
HIV: human immunodeficiency virus; LT: liver transplantation; ND: Not
11
described; RD: Rheumatic diseases
ly
On
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
15
The Journal of Dermatology
Page 16 of 18
Page 17 of 18
ev
rR
Fo
Figure 1. Box-and-whisker plot shows the day of onset of each adverse event
iew
380x260mm (72 x 72 DPI)
ly
On
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
The Journal of Dermatology
The Journal of Dermatology
The Journal of Dermatology
Table 1 Patient characteristics
Our cases
(n= 132)
Adverse events
P value
(n= 32)
Age (average± standard deviation)
60.6± 17.8
59.0± 18.0
0.54
Sex (man/woman)
60/72
10/22
Bullous pemphigoid (%)
28
7 (25%)
0.97
Dermatomyositis (%)
22
6 (27.7%)
0.9
Pemphigus vulgaris (%)
3 (33.3%)
0.83
Pyoderma gangrenosum (%)
1 (14.3%)
0.82
Adult still's disease (%)
2 (33.3%)
0.86
Malignant lymphoma (%)
1 (20%)
0.94
Systemic lupus erythematosus (%)
2 (40%)
0.78
Pemphigus foliaceus (%)
1 (20%)
0.94
45
9 (20%)
0.78
Primary disease
iew
ev
rR
Others (%)
Fo
ly
On
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Page 18 of 18
The Journal of Dermatology
Page 19 of 18
Table 2 The incidence of adverse events comparison with previous reports
This study
Disease
#7
Dermatological diseases
#8
RD
After
LT
#9
#10
Patients infected
with HIV
Daily dose
of Trimethoprim (mg)
80
40
160 320
80
ND
80
160
320
Daily dose of
Sulfamethoxazole (mg)
400
200
800 1600
400
ND
400
800
1600
Every Daily or
Twice
other thriceweekly
day weekly
Dosing
interval
Total
Number of
cases
132
Adverse
events (%)
32
29
(24.2) (25.2) (14.3) (50)
Daily
115
Hematologic 20
18
(%)
(15.2) (15.7) (14.3)
(2.6) (2.6)
Leukocytopenia (%)
(2.2) (2.6)
Thrombocytopenia (%)
17
15
(12.5) (13.0) (14.3)
Twice Thrice
P value*
weekly weekly
262
60
1312 1313
104
(50)
34
(13.0)
11
255 126
(18.3) (19.4) (9.6)
ND
0.15
(2.3)
72
17
(10.0) (5.5) (1.3)
ND
<0.0001
(0.8)
ND
ND
ND
21
ND
(20.2)
(0.4)
ND
(5.0)
ND
39
ND
(37.5)
(50)
(1.2)
ND
(5.0)
ND
11
ND
(10.6)
(50)
ev
Erythrocytopenia (%)
Daily
rR
Fo
iew
Elevated liver 8
enzyme (%) (5.9) (7.0)
(2.3)
11
(5.0) (0.8) (0.2)
Renal dysfunction (%)
(1.5) (1.7)
(1.9)
ND
(0.5) (0.2)
ND
0.16
Drug
eruption (%)
(4.5) (4.3)
(50)
(2.7)
ND
ND
(8.7)
ND
Intestinal
problem (%)
(0.8)
24
10
(3.3) (1.8) (0.8)
Hypersensitivity (%)
ND
ND
ND
ND ND
ND
ND
ND
130 86
(9.9) (6.5)
ND
Others
(%)
ND
(3.4%)
(0.5) (0.3)
14
0.48
(13.5)
ly
On
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
The Journal of Dermatology
ND
18
<0.00001
(17.3)
17
0.16
(16.3)
Daily administered cases of this study versus daily administered cases of El-Sadr WM, et al.
HIV: human immunodeficiency virus; LT: liver transplantation;
ND: Not described; RD: Rheumatic diseases
The Journal of Dermatology
ND
...
論文の公開元へ
